BAM-15
Mitochondrial Uncoupler · Metabolic Enhancer
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.
Overview
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.
BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Reduces body fat by increasing energy expenditure and fat oxidation without reducing food intake.
Research shows reversal of diet-induced insulin resistance in mouse models.
Addresses multiple components of metabolic syndrome through enhanced energy expenditure.
2024 research shows combining BAM-15 with semaglutide produces stronger metabolic benefits than either alone by countering metabolic adaptation.
May help overcome weight loss plateaus by preventing metabolic adaptation/efficiency.
Research shows decreased liver triglycerides in treated animals.
Improved glucose tolerance observed in research models.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Small molecule (not a peptide)
- Molecular weight
- 326.28 Da
- Half-life
- ~1.7 h
- Typical dose
- 25-50 mg oral
- Frequency
- Once or twice daily with meals
- Cycle length
- 4-8 weeks based on research protocols
- Storage
- Room temperature, protect from light and moisture
Molecular data
- Type
- Small molecule (not a peptide)
- Molecular weight
- 326.28 Da
- Half-life
- 102 min
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Metabolic enhancement | Oral | 25-50 mg | Once or twice daily |
| Research protocol (mouse equivalent) | Oral gavage | ~10 mg/kg | Daily |
Interactions
2024 research shows combination produces stronger metabolic benefits by countering metabolic adaptation that limits GLP-1 efficacy.
Similar synergy expected as with semaglutide; helps overcome weight loss plateaus.
Do not combine with other mitochondrial uncouplers - dangerous additive effects possible.
Both increase metabolic rate; combination requires careful monitoring.
Both affect mitochondrial function but through different mechanisms.
Quality checklist
- ✓White to off-white powder or tablets
- ✓Certificate of analysis with purity >98%
- ✓Proper packaging protected from light
- ✓Reputable supplier
- !No third-party testing available
- !Unclear sourcing
- ×Discolored product
- ×No purity information
- ×Unknown origin
What to expect
Safety
- Generally well-tolerated in research
- Possible mild increase in body temperature (less than DNP)
- Significant hyperthermia/overheating
- Excessive sweating
- Rapid heart rate
- Difficulty breathing
- Hyperthyroidism or thyroid disorders
- Heart conditions
- Pregnancy or breastfeeding
- Use of other mitochondrial uncouplers (DNP, FCCP)
- Fever or active infection
FAQ
How does BAM-15 avoid the dangerous hyperthermia of DNP?
BAM-15 is approximately 7-fold more potent than DNP but does not induce the dangerous, uncontrollable hyperthermia DNP causes. BAM-15 enhances mitochondrial proton permeability selectively without depolarizing plasma membranes or triggering systemic heat production. It activates compensatory AMPK and PGC-1α pathways instead of creating metabolic chaos.
Can BAM-15 cause fat loss without diet and exercise?
Research in mice showed BAM-15 reduced body fat without affecting food intake or body temperature, but those were sedentary rodents. Human efficacy requires unclear interaction with actual behavior, diet, and exercise. Results are likely enhanced by caloric deficit and training, not achieved passively.
Why does 2024 research show BAM-15 works better with semaglutide?
Combining BAM-15 (mitochondrial uncoupler) with semaglutide (GLP-1 agonist) produces stronger metabolic benefits than either alone by countering metabolic adaptation. Semaglutide's appetite suppression plateaus as the body adapts; BAM-15's energy expenditure boost prevents this adaptation, allowing sustained weight loss.
Is BAM-15 safer than other mitochondrial uncouplers like FCCP?
Yes. Unlike FCCP and traditional uncouplers like DNP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective doses. This selective mitochondrial targeting makes it substantially safer, though human safety data remains limited. It's still a research chemical without FDA approval.
References
- 1Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in miceNature Communications · 2020
BAM15 is orally bioavailable, increases nutrient oxidation, decreases body fat mass without altering food intake, lean mass, body temperature, or markers of toxicity.
animalSource ↗ - 2BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic controlEMBO Molecular Medicine · 2020
BAM15 is 7-fold more potent than DNP, does not depolarize plasma membranes, and does not induce apoptosis at effective doses.
reviewSource ↗ - 3BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseasesPMC Review · 2023
Comprehensive review of BAM15 mechanisms including AMPK and PGC-1α activation pathways.
reviewSource ↗ - 4Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese miceClinical Science · 2024
Combining semaglutide and BAM15 produces stronger metabolic benefits than either alone; helps overcome metabolic adaptation.
animalSource ↗